WallStSmart

ABVC Biopharma Inc (ABVC)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ABVC Biopharma Inc generates 8% more annual revenue ($797,920 vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. ABVC earns a higher WallStSmart Score of 26/100 (F).

ABVC

Avoid

26

out of 100

Grade: F

Growth: 5.3Profit: 3.0Value: 6.7Quality: 5.0
Piotroski: 4/9Altman Z: -5.50

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABVCUndervalued (+68.8%)

Margin of Safety

+68.8%

Fair Value

$5.54

Current Price

$1.33

$4.21 discount

UndervaluedFair: $5.54Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABVC2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
104.5%10/10

Revenue surging 104.5% year-over-year

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

ABVC4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$35.36M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ABVC

The strongest argument for ABVC centers on Revenue Growth, Debt/Equity. Revenue growth of 104.5% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ABVC

The primary concerns for ABVC are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

ABVC profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

ABVC is growing revenue faster at 104.5% — sustainability is the question.

ABVC generates stronger free cash flow (-894,243), providing more financial flexibility.

Bottom Line

ABVC scores higher overall (26/100 vs 24/100) and 104.5% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ABVC Biopharma Inc

HEALTHCARE · BIOTECHNOLOGY · USA

American BriVision (Holding) Corporation, a clinical-stage biopharmaceutical company, develops drugs and medical devices to meet unmet medical needs in the United States.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?